23日，华大生命科学研究院与之江实验室联合发布全球首个百亿参数可部署的基因组通用基础模型 Genos。该模型支持多达百万碱基对的超长上下文分析，并实现单碱基分辨率的精准识别。 人类基因组由30亿对碱基组成。"人类基因组计划"破译了序列，但序列上碱基的具体功能仍需要精准识 别和解析。 （文章来源：科技日报） 测试结果显示，Genos在直接面向临床应用的致病性突变解读任务中，准确率达92%；结合科学基础模 型后，准确率高达98.3%。多项综合评测结果也显示，Genos超越现有最佳水平模型。 华大生命科学研究院相关负责人说，Genos模型已在HuggingFace（抱抱脸）、魔搭等平台全面开源开 放，提供12亿和100亿参数两个版本，满足不同需求。 现有模型大多基于1—2个参考基因组开展训练，难以体现人类遗传资源的多样性。而Genos整合了人类 泛基因组参考联盟（HPRC）、人类基因组结构变异图谱计划（HGSVC）等多个权威公开资源，首次 将全球范围内636个"端粒到端粒"级别的高质量人类基因组作为训练数据。这些数据覆盖了全球不同人 群，有助更全面理解人类遗传多样性。 算法架构方面，Genos通过"混合专家"架构， ...

Core Insights - The article discusses the perspectives of four leading economists on global asset allocation and investment opportunities in China, particularly in the technology sector and gold as a safe-haven asset [2]. Group 1: Economic Perspectives - CICC's chief economist, Peng Wensheng, attributes the strong performance of the A-share market to a decrease in risk premium rather than improvements in corporate earnings, indicating a significant improvement in market expectations since last year [5]. - Guosen Securities' chief economist, Xun Yugen, believes the current bull market began on September 24, 2024, and compares it to the "5.19 Bull Market" of 1999, suggesting that the current market is still in its early stages [7]. - Xun Yugen also emphasizes that the bull market is driven by fundamentals, particularly in the technology sector, and suggests a rotation towards undervalued sectors like real estate and consumer goods [10]. Group 2: Investment Opportunities in China - Morgan Stanley's chief China equity strategist, Wang Ying, notes that global investors have a relatively low allocation to Chinese stocks, indicating a trend towards increasing investment in high-tech sectors such as AI and automation [11]. - Wang Ying forecasts that global GDP growth will slow from 3.0% in 2025 to 2.8% in 2026, with inflation rates expected to remain stable, providing central banks with policy flexibility [14]. Group 3: Global Monetary Policy and Gold - UBS's Hu Yifan highlights the global trend of declining interest rates, which, along with strong corporate earnings and advancements in AI, presents new investment opportunities [16]. - There is a consensus among economists regarding the value of gold in asset allocation, with Wang Ying predicting at least a 5% increase in gold prices due to historical performance during rate-cutting cycles and geopolitical uncertainties [20]. - Hu Yifan supports the view that holding gold is a good strategy for diversifying investments and hedging against risks, especially in light of the recent depreciation of the US dollar [21]. Group 4: Global Market Differentiation - In terms of global stock market allocation, Morgan Stanley suggests an equal-weight strategy but notes significant regional differentiation, favoring the US market for its scale and quality [24]. - The firm recommends focusing on high-quality stocks and cyclical stocks in the US while being cautious about trade uncertainties that could lead to market volatility [24]. - For emerging markets, Morgan Stanley prefers domestically oriented companies and financial stocks, avoiding exporters and semiconductor hardware firms [25].

Core Viewpoint - The current investment opportunities are rated at 4 out of 10, indicating a challenging market environment with high valuations and low investor sentiment [5][122]. Group 1: Investment Philosophy - The essence of value investing lies in the combination of contrarian thinking and analytical skills, requiring investors to assess asset values while questioning market consensus [86][90]. - The market is inherently inefficient due to human emotions such as greed and fear, which creates opportunities for value investors [52][60]. - A flexible investment approach based on fundamental analysis is essential, as extreme market conditions can lead to significant mispricing of assets [54][55]. Group 2: Investment Strategy - Baupost Group employs a broad investment strategy, focusing on various asset classes including public equities, private equity, public credit, private credit, and real estate, adjusting allocations based on market opportunities [79][80]. - The firm emphasizes maintaining a margin of safety by purchasing undervalued assets, ensuring that even partial price corrections can yield satisfactory returns [78][79]. - The investment team operates with a "mile wide, mile deep" approach, allowing for quick identification of opportunities while also enabling deep dives into specific investments when necessary [73][78]. Group 3: Market Conditions - Current market conditions are characterized by high valuations, with the S&P 500 recently reaching historical highs, while macroeconomic fundamentals remain uncertain [122][125]. - The credit market has seen a significant rebound, but the narrowing of spreads and potential interest rate cuts may diminish future investment opportunities [128]. - Commercial real estate is highlighted as a particularly interesting area, with signs of recovery in the office market leading to increased buying activity [130][131]. Group 4: Role of Technology - AI is viewed as a tool to enhance efficiency rather than a replacement for critical thinking, with the firm using it to streamline data analysis and improve research processes [135][136]. - The application of AI in investment analysis is still evolving, and while it can assist in data processing, it should not replace independent thought and judgment [140][141]. Group 5: Importance of Management - The significance of management teams in investment decisions is increasing, as understanding their intentions and strategies is crucial for assessing long-term value [97][98]. - Engaging with management allows investors to gauge their commitment to shareholder value and the direction of the company [98][99]. Group 6: Client Relationships - Establishing a long-term, patient investor base is critical for investment success, requiring clear communication of expectations and ongoing education for clients [100][110]. - The firm prioritizes aligning with clients who share a similar investment philosophy to foster a collaborative and trusting relationship [102][106].

Investment Rating - The report assigns a "Buy" rating to the company, Kolun Biotechnology (6990 HK), with a target price of HKD 549.00, indicating a potential upside of 16.6% from the current closing price of HKD 471.00 [6][13]. Core Insights - The report highlights the significant clinical advancements of the company's ADC products, particularly Sac-TMT, which has set a new benchmark for treating EGFR mutation-resistant NSCLC. The results from the Phase III OptiTROP-Lung04 study showed a median progression-free survival (PFS) of 8.3 months compared to 4.2 months for the control group, with a hazard ratio (HR) of 0.49 [2]. - The report also notes that the application for market approval for Sac-TMT was granted in October, further enhancing the company's growth prospects [2]. - The financial forecasts for the company have been adjusted upwards, with revenue projections for 2025-2027 increased by 0-5%, leading to a peak sales forecast of RMB 64 billion for Sac-TMT and RMB 11 billion for another product [7]. Financial Performance - The company is projected to generate revenues of RMB 2,050 million in 2025, with a gross profit of RMB 1,322 million, maintaining a gross margin of 64.5% [7][14]. - The net profit for 2026 is expected to turn positive at RMB 50 million, with a significant increase to RMB 751 million by 2027 [7][14]. - The company's market capitalization is approximately HKD 76.66 billion, with a year-to-date stock price increase of 188.43% [4]. Valuation Model - The DCF valuation model estimates the equity value of the company at approximately RMB 116.38 billion, translating to a per-share value of HKD 549.00 [8]. - The model incorporates a perpetual growth rate of 3% and a weighted average cost of capital (WACC) of 9.4% [8]. Stock Performance - The stock has shown a strong performance over the past year, with a significant increase compared to the Hang Seng Index [3]. - The 52-week high for the stock is HKD 577.50, while the low is HKD 154.00, indicating substantial volatility and growth potential [4]. Clinical Data Highlights - The report emphasizes the clinical efficacy of Sac-TMT in treating NSCLC and HR+/HER2- breast cancer, with significant improvements in PFS and overall survival (OS) rates compared to existing therapies [2][6]. - The company is well-positioned to capitalize on the growing ADC market, supported by robust clinical data and regulatory approvals [7].

Core Viewpoint - The pharmaceutical sector experienced a decline in early trading, with various indices reflecting negative performance, while the Hang Seng Innovation Drug ETF saw significant net subscriptions, indicating investor interest despite the overall downturn [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovation Drug Index fell by 2.6% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 2.2% [1] - The CSI Innovation Drug Industry Index dropped by 0.5% [1] - The CSI Biotechnology Theme Index declined by 0.6% [1] - The CSI 300 Pharmaceutical and Health Index fell by 0.8% [1] Group 2: Investment Activity - The Hang Seng Innovation Drug ETF (159316) recorded over 60 million net subscriptions, showing resilience against market trends [1] - The ETF attracted more than 900 million yuan in inflows during the month, ranking among the top in Hong Kong's innovation drug-related products [1]

Core Viewpoint - The "15th Five-Year Plan" (referred to as "15th Plan") is crucial for China's economic and social development from 2026 to 2030, with a draft to be submitted for review in March next year [4]. Group 1: Economic Context - China is the world's second-largest economy by nominal GDP and the largest by purchasing power parity, playing a significant role in global economic growth and consumption of major commodities [4]. - The government faces challenges due to the ongoing decline in the real estate market since 2021, which has impacted the economy [4]. Group 2: Planning and Goals - The government is likely to avoid setting specific growth targets for the "15th Plan," focusing instead on high-quality development, resilience, safety, and inclusiveness, with annual growth targets set later [5]. - A potential growth target of "around 4.5%" for 2026 is anticipated, gradually shifting to "around 4%" by 2030 [5]. Group 3: Investment and Policy Focus - Continued investment and industrial policies will be directed towards achieving technological self-reliance, particularly in semiconductors, artificial intelligence, and biotechnology [5]. - The traditional economy, centered around the real estate sector, will remain a growth pillar while efforts to address real estate market debt and fiscal system repair are expected [5]. Group 4: Social Welfare Reforms - The government may reform the social welfare system, especially the pension system, to achieve income redistribution, with significant increases in basic pension payments for low-income families and enhanced medical insurance subsidies [5].

Core Viewpoint - The conference highlighted the optimistic outlook for Chinese assets, particularly in the technology sector, amidst a global trend of investment diversification and a consensus on the value of gold as a hedge [2][16]. Group 1: Market Performance and Economic Insights - The A-share market's strong performance is attributed to a decline in risk premiums rather than improvements in corporate earnings, indicating improved market expectations [4]. - The current bull market is believed to have entered its second phase, driven by fundamental improvements in technology sectors, with a focus on value sectors like real estate and consumer goods [7][9]. - The global economic outlook suggests a slowdown in GDP growth from 3.0% in 2025 to 2.8% in 2026, with inflation rates expected to remain stable, providing central banks with policy flexibility [12]. Group 2: Investment Strategies and Recommendations - Investment in Chinese assets is expected to increase, particularly in high-tech sectors such as AI, automation, and biotechnology, as global investors recognize the potential for growth [10][22]. - A diversified approach to global stock markets is recommended, with a preference for U.S. stocks due to their scale and quality, while being cautious of trade uncertainties that could impact market stability [19]. - The consensus among economists is to increase allocations in gold as a strategic asset, with expectations of at least a 5% price increase due to historical performance during rate cuts and geopolitical uncertainties [17][18]. Group 3: Regional Market Analysis - In the U.S. market, there is a preference for high-quality and cyclical stocks, while in Japan, companies benefiting from domestic inflation and governance reforms are favored [19][20]. - European markets face growth challenges, with a projected GDP growth of only 1% in 2025, suggesting a focus on resilient sectors like defense and banking [20]. - Emerging markets are viewed favorably for domestic-oriented companies and financial stocks, while exporters and semiconductor hardware firms are advised against [21].

天眼查App显示，近日，河北鑫煜农生物科技有限公司成立，法定代表人为韩秀喜，注册资本300万人 民币，经营范围为许可项目：饲料生产;农药零售;农药批发;检验检测服务（依法须经批准的项目，经相 关部门批准后方可开展经营活动，具体经营项目以批准文件或许可证件为准）一般项目：化肥销售;肥 料销售;农业机械服务;农林牧副渔业专业机械的安装、维修;农林牧渔机械配件销售;生物有机肥料研发; 土壤与肥料的复混加工;海洋生物活性物质提取、纯化、合成技术研发;复合微生物肥料研发;工程和技术 研究和试验发展;技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;农产品的生产、销 售、加工、运输、贮藏及其他相关服务;农林牧渔业废弃物综合利用;农作物病虫害防治服务;林业专业及 辅助性活动;农业专业及辅助性活动;农作物栽培服务;农作物种子经营（仅限不再分装的包装种子）（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

Core Insights - A total of 37 Chinese concept stocks have returned to the Hong Kong market through dual primary listings or secondary listings as of October 21, with 24 companies opting for dual primary listings and 13 for secondary listings [1][4] - The return of Chinese concept stocks is primarily driven by companies in the frontier technology sector, including smart driving, biotechnology, and advanced manufacturing [1][6] - The Hong Kong Stock Exchange (HKEX) offers significant advantages in terms of listing time, procedures, costs, and exemption conditions, which is expected to facilitate the continued return of Chinese concept stocks [1][6] Group 1 - Recent dual primary listings include smart driving companies WeRide and Pony.ai, which have both passed the HKEX hearing and are set to list [2] - The dual primary listing strategy is seen as crucial for smart driving companies to expand financing channels, enhance valuation stability, and connect with core markets [2] - Biotech companies are also planning dual primary listings, with Tianjing Biotechnology announcing its intention to conduct an IPO in Hong Kong [2] Group 2 - Hesai Technology became the first lidar company to achieve a dual primary listing, raising over 4.16 billion HKD, marking the largest IPO by a Chinese concept stock returning to Hong Kong in nearly four years [3] - The return of high-quality Chinese concept stocks to the Hong Kong market is supported by favorable policies and ongoing market reforms [4] - The HKEX has introduced mechanisms such as "same share, different rights" and relaxed listing requirements for unprofitable biotech firms, enhancing its capacity to accommodate Chinese concept stocks [4]

Core Insights - A total of 37 Chinese concept stocks have returned to the Hong Kong market through dual primary listings or secondary listings as of October 21, indicating a significant trend of quality Chinese companies returning to Hong Kong [1][4] - The technology sector, particularly in areas such as smart driving, biotechnology, and advanced manufacturing, has become a new driving force for the return of Chinese concept stocks to Hong Kong [1][5] - The Hong Kong Stock Exchange (HKEX) offers advantages in terms of listing time, procedures, costs, and exemption conditions, which are expected to facilitate the continued return of Chinese concept stocks [1][5] Group 1: Recent Listings - Smart driving companies, such as WeRide and Pony.ai, have recently passed the HKEX hearing, indicating their imminent dual primary listings on both NASDAQ and HKEX [2] - The dual primary listing is strategically significant for smart driving companies as it broadens financing channels and enhances valuation stability [2] Group 2: Market Trends - The return of quality Chinese concept stocks to the Hong Kong market is supported by favorable policies and ongoing reforms in the Hong Kong market [4][5] - The average daily trading volume in the Hong Kong market has increased by 132% year-on-year, reaching 2,483 billion HKD in the first eight months of this year, reflecting enhanced liquidity [5] Group 3: Policy Support - The China Securities Regulatory Commission (CSRC) has expressed support for quality Chinese concept stocks to return to the domestic and Hong Kong markets [4] - The Hong Kong government has also indicated its commitment to making Hong Kong the preferred return destination for Chinese concept stocks [4]